SCHEMBL318779

SCHEMBL318779

CC=C(CCC(=O)O)C(C)=O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 4/20 0.50
SLC15A2 Q16348 1/20 0.50
EGLN1 Q9GZT9 6/20 0.47
ALKBH5 Q6P6C2 1/20 0.47
SUCNR1 Q9BXA5 1/20 0.47
PHF8 Q9UPP1 7/20 0.42
KDM2A Q9Y2K7 7/20 0.42
KDM5C P41229 4/20 0.42
KDM4E B2RXH2 3/20 0.42
KDM6B O15054 3/20 0.42
FFAR3 O14843 1/20 0.39
HDAC3 O15379 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
MAPK1 P28482 1/20 0.38
SLC13A3 Q8WWT9 1/20 0.38
OR51E2 Q9H255 1/20 0.38
SLC22A6 Q4U2R8 2/20 0.36
RECQL P46063 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318778 1.00 LMNA (0.50) LMNASLC15A2EGLN1ALKBH5SUCNR1
SCHEMBL9044511 0.81 EGLN1 (0.50) LMNASLC15A2EGLN1ALKBH5SUCNR1
SCHEMBL6905084 0.81 EGLN1 (0.50) LMNASLC15A2EGLN1ALKBH5SUCNR1
SCHEMBL13639033 0.80 RECQL (0.31) KDM4ERECQL
Methacrylic Acid SCHEMBL28134789 0.77 LMNA (0.42) LMNASLC15A2EGLN1ALKBH5SUCNR1
Succinic Acid SCHEMBL28874138 0.76 EGLN1 (0.69) LMNASLC15A2EGLN1ALKBH5SUCNR1
SCHEMBL27476486 0.75 EGLN1 (0.43) LMNASLC15A2EGLN1ALKBH5SUCNR1
Succinic Acid SCHEMBL28844915 0.74 EGLN1 (0.64) LMNASLC15A2EGLN1ALKBH5SUCNR1
Succinic Acid SCHEMBL28874136 0.74 LMNA (0.65) LMNASLC15A2EGLN1ALKBH5SUCNR1
Succinic Acid SCHEMBL9995358 0.74 LMNA (0.65) LMNASLC15A2EGLN1ALKBH5SUCNR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2590968-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS Novartis AG (CH) 2013-05-15 EP disclosed
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2013-05-02 US disclosed
WO-2012004217-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS NOVARTIS AG (CH) 2012-01-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109682-A1 CYCLIC ETHER COMPOUNDS USEFUL AS KINASE INHIBITORS PIM1, GSK3A, GSK3B LMNA 1799/4885SLC15A2 3287/4885EGLN1 1104/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.